Catalent (NYSE:CTLT) said today that it closed its acquisition of Canada-based Accucaps and its pharmaceutical soft-gel manufacturing capabilities. The Somerset, N.J.-based company did not disclose the deal’s financial details.
In November, Catalent said that it planned to fund the Accucaps buy with a $400 million debt offering.
Get the full story at our sister site, Drug Delivery Business News.